IP Library Granted Patent US 10,556,920
Granted Patent B2
US 10,556,920 · App. 15/850,388 · Granted Feb 11, 2020

Phosphorus-containing heterocycles and a method for making and using

Inventors: Chris Vonnegut (Springfield, OR); Airlia Shonkwiler (West Linn, OR); Michael Haley (Eugene, OR); Darren Johnson (Eugene, OR)
Assignee: University of Oregon
C07F9/65846A61K31/395A61K31/662C07F9/657172C09K11/06C09K2211/104
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,556,920
App. No.
15/850,388
Granted
Feb 11, 2020
Kind
B2
Abstract

Disclosed embodiments concern a phosphorus-containing heterocyclic compound according to the formula One exemplary compound is Certain embodiments fluoresce with excitation by light. The compounds are useful as fluorescent probes and as bioisosteres. In some embodiments, the compounds are bioisosteres of alpha-quinolones. Also disclosed is a method for making the compounds.

Claims (57)

1. A compound of formula I

or a pharmaceutically acceptable salt thereof, wherein:

ring A is aryl;

X is NR 3 ;

Y is CR 4 ;

Z is CR 4 ;

R 1 is —OH, aryl, heteroaryl, —O-aliphatic, —O-aryl, —O-heteroaryl, —O-heterocyclic, or —O-heteroaliphatic;

R 2 is oxo (═O), or ═S;

R 3 is H, aliphatic, heteroaliphatic, heterocyclic, heteroaryl, acyl, carboxyl ester, or a lone pair of electrons;

each R 4 independently is H, aliphatic, heteroaliphatic, aryl, heterocyclic, heteroaryl, halo, CN, NO 2 , sulfonyl, amino, carboxyl, carboxyl ester, aminosulfonyl, or aminocarbonyl; and

“---” represents a bond that may or may not be present.

2. The compound of claim 1 , wherein R 1 is —OH, aryl, heteroaryl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-cycloalkyl, —O-cycloalkenyl, —O-cycloalkynyl, —O-aryl, —O-heteroaryl, —O-heterocyclic, —O-heterocycloaliphatic, —O-heteroalkyl or —O— heterocycloalkyl.

3. The compound of claim 1 , wherein R 2 is oxo.

4. The compound of claim 1 , wherein R 3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclic, heterocycloaliphatic, heteroalkyl, heterocycloalkyl, carboxyl ester, or a lone pair of electrons.

5. The compound of claim 1 , wherein each R 4 independently is H, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heterocyclic, heterocycloaliphatic, heteroalkyl, heterocycloalkyl, halo, CN, NO 2 , sulfonyl, amino, carboxyl, aminosulfonyl, aminocarbonyl, or —CO 2 R where R is aryl or heteroaryl.

6. The compound of claim 1 , wherein ring A is phenyl, or naphthyl.

7. The compound of claim 6 , wherein ring A is phenyl.

8. The compound of claim 1 , wherein Z is CH.

9. The compound of claim 1 , wherein each R 4 independently is alkyl, cycloalkyl, aryl or heteroaryl.

10. The compound of claim 9 , wherein each R 4 independently is 2-pyridyl, phenyl, 4-NC-phenyl, 4-EtOC(O)-phenyl, 4-methoxyphenyl, 3,5-bis(trifluoromethyl)phenyl, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, n-pentyl or cyclopentyl.

11. The compound of claim 1 , wherein R 1 is —O-phenyl, methoxy, ethoxy, propoxy, cyclopropoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, phenyl, pyridyl, thienyl.

12. The compound of claim 11 , wherein R 1 is —O-phenyl, phenyl, or thienyl.

13. The compound of claim 11 , wherein R 1 is —O-phenyl, and R 2 is oxo.

14. The compound of claim 1 , wherein the compound has a structure according to

wherein

R 5 , R 6 , R 7 and R 8 independently are H, aliphatic, haloalkyl, heteroaliphatic, aryl, heterocyclic, heteroaryl, —O-aliphatic, —O-heteroaliphatic, —O-heterocyclic, —O-heteroaryl, —O-aryl, halo, OH, CN, NO 2 , sulfonyl, amino, carboxyl, carboxyl ester, aminosulfonyl, or aminocarbonyl or any two adjacent groups together form an aliphatic, heterocyclic, aryl or heteroaryl ring.

15. The compound of claim 1 , wherein the compound has a structure according to

wherein L is a bond, aliphatic, aryl, heteroaryl, heteroaliphatic, or heterocyclic; and

each R 5 , R 6 , and R 7 independently is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, aryl, heteroaryl, heterocyclic, heterocycloaliphatic, heteroalkyl, heterocycloalkyl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-heteroaliphatic, —O-heterocyclic, —O— heteroaryl, —O-aryl, halo, CN, NO 2 , sulfonyl, amino, carboxyl, carboxyl ester, aminosulfonyl, or aminocarbonyl or any two adjacent groups together form an aliphatic, heterocyclic, aryl or heteroaryl ring.

16. The compound of claim 15 , wherein:

L is phenyl; or

each R 5 , R 6 , and R 7 is H; or

L is phenyl and each R 5 , R 6 , and R 7 is H.

17. The compound of claim 1 , wherein the compound is selected from:

4-(2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

ethyl 4-(2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzoate;

2-phenoxy-3-phenyl-1H-benzo[e][1,2]azaphosphinine 2-oxide;

3-(4-methoxyphenyl)-2-phenoxy-1H-benzo[e][1,2]azaphosphinine 2-oxide;

3-pentyl-2-phenoxy-1H-benzo[e][1,2]azaphosphinine 2-oxide;

2-phenoxy-3-(pyridin-2-yl)-1H-benzo[e][1,2]azaphosphinine 2-oxide;

4-(2-oxido-2-phenoxy-1H-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-e][1,2]azaphosphinin-3-yl)benzonitrile;

6-(tert-butyl)-2-phenoxy-3-(pyridin-2-yl)-1H-benzo[e][1,2]azaphosphinine 2-oxide;

3-(3,5-bis(trifluoromethyl)phenyl)-6-(tert-butyl)-2-phenoxy-1H-benzo[e][1,2]azaphosphinine 2-oxide;

4-(3-oxido-3-phenoxy-4H-naphtho[1,2-e][1,2]azaphosphinin-2-yl)benzonitrile;

4-(2-oxido-2-phenoxy-1H-naphtho[2,3-e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(2-oxido-2-phenoxy-1H-naphtho[2,1-e][1,2]azaphosphinin-3-yl)benzonitrile;

4,4′-(1,4-phenylenebis(2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinine-8,3-diyl))dibenzonitrile;

4,4′-(1,3-phenylenebis(2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinine-8,3-diyl))dibenzonitrile;

4,4′-(1,2-phenylenebis(2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinine-8,3-diyl))dibenzonitrile;

4-(1-benzyl-2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(1-acetyl-2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(2-oxido-2-phenyl-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(2-oxido-2-(thiophen-3-yl)-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(1-methyl-2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(1-ethyl-2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile;

4-(1-isopropyl-2-oxido-2-phenoxy-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile; or

4-(2-oxido-2-(thiophen-2-yl)-1H-benzo[e][1,2]azaphosphinin-3-yl)benzonitrile.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: VONNEGUT, CHRIS; SHONKWILER, AIRLIA; HALEY, MICHAEL; JOHNSON, DARREN
To: UNIVERSITY OF OREGON
Reel/Frame 044870/0226 →
CONFIRMATORY LICENSE Recorded Dec 28, 2017
From: UNIVERSITY OF OREGON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044968/0958 →
Continuity (3)
Continuation In Part PCTUS2016038813 · Jun 22, 2016
Provisional Application 62183477 · Jun 23, 2015
Related Publication 20180118769A1 · May 3, 2018